IL8 Biomarker Stratification for PD-L1 Antagonist Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly for bladder and kidney cancers, face challenges in timely detection and effective treatment due to the suppression of immune responses by PD-L1, leading to poor outcomes and limited therapeutic options.
Innovation Solution
Determining the expression level of IL8 in patient samples to identify individuals likely to respond to PD-L1 binding antagonist therapies, allowing for personalized treatment approaches by administering effective anti-cancer therapies based on IL8 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-L1 binding antagonist therapy is administered to cancer patients, then treatment efficacy is improved, but not all patients respond equally well due to heterogeneity in immune response
Solution Approach 1:
The patent applies parameter changes by measuring IL8 expression levels (a quantitative biomarker parameter) to stratify patients into different treatment groups. Patients with specific IL8 expression thresholds are selected for PD-L1 antagonist therapy, optimizing treatment response based on this measurable parameter variation among individuals.
Solution Approach 2:
The patent applies local quality by tailoring treatment approaches to specific patient subgroups based on their IL8 expression characteristics. Rather than treating all patients uniformly, the therapy is customized to match the local biological characteristics (IL8 expression level) of each patient population, thereby improving overall treatment efficacy.
2Measurement precision
If comprehensive patient profiling including multiple biomarkers is performed, then treatment selection accuracy is improved, but diagnostic complexity and time requirements increase
Solution Approach 1:
The patent applies the extraction principle by isolating and focusing on a single critical biomarker (IL8) rather than measuring multiple biomarkers simultaneously. This extraction of the most predictive marker simplifies the diagnostic workflow while maintaining high accuracy in patient stratification for PD-L1 antagonist therapy selection.
Data Source
AI summary
The present invention provides therapeutic and diagnostic methods and compositions for cancer (e.g., bladder cancer (e.g., UC) or kidney cancer (e.g., RCC)). The invention provides methods of identifying an individual having a cancer who is likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, methods for selecting a therapy for an individual having a cancer, methods of identifying an individual having a cancer who is less likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist monotherapy, methods of monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, and methods of treating an individual having cancer, based on expression levels of a biomarker of the invention (e.g., one or more genes set forth in any one of Tables 1-7, e.g., IL8).